NEW YORK , Oct. 17, 2024 /PRNewswire/ -- The National Kidney Foundation (NKF) Innovation Fund is proud to announce its latest investment in Revalia Bio, an innovative health technology company focused on creating a new paradigm in how we develop and deliver personalized care for kidney disease patients. This investment will help accelerate Revalia Bio's efforts to transform the future of care for patients facing chronic kidney disease (CKD) and related conditions, offering new hope to millions of people affected by kidney disease worldwide.
Revalia Bio's technology is centered around the use of human organs donated for research, which are revived using advanced organ perfusion methods. Perfusion is a process where fluids, similar to blood, are circulated through the organ to keep it functioning outside the body. This allows Revalia Bio to study human organs in a near-living state, generating real-time data that provides a new window into human biology and disease.
This unique approach creates an entirely new source of human data that can be coupled with the latest advances in AI to improve both the efficiency and quality of the drug development process. "This investment serves as an important catalyst for advancing how new therapies are developed and delivered," said Kevin Longino , CEO of the National Kidney Foundation and a kidney transplant recipient. "Revalia Bio's approach will accelerate the integration of innovative treatments for kidney disease by leveraging human org.